GAITHERSBURG, Md., Oct. 3, 2014 (GLOBE NEWSWIRE) -- GlycoMimetics, Inc. (Nasdaq:GLYC) today announced that CEO Rachel King will provide a company presentation at the 13th Annual BIO Investor Forum on Tuesday, October 7, 2014 at 1:30 p.m. Eastern Time. Hosted by the Biotechnology Industry Organization (BIO), the Conference will take place October 7-8 at the Palace Hotel in San Francisco.
To access the live webcast and subsequent archived recordings for the presentation, please visit the GlycoMimetics website at www.glycomimetics.com.
Ms. King will also participate in the conference's Closing Plenary Session, Up, Up, and Away: How Fragile is the Biotech Rally After Five Positive Years?, on October 8 at 3:30 p.m.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Pfizer, the company's development partner for rivipansel, a GlycoMimetics-developed investigational therapy for pain crisis associated with sickle cell disease, is preparing for a Phase 3 clinical study. A GlycoMimetics wholly-owned candidate therapy for acute myeloid leukemia (AML) and other blood disorders is also in clinical trials. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Learn more at www.glycomimetics.com.
CONTACT: Brian Hahn Email: firstname.lastname@example.org Phone: 240-243-1207Source:GlycoMimetics, Inc.